CD44 exon v6 correlates with cellular differentiation but not with progression and metastasis of cervical cancer

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2107-2111

  Tokumo, K ^a   Kodama, J ^a   Seki, N ^a   Miyagi, Y ^a   Yoshinouchi, M ^a   Kudo, T ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

CD44v6; Cervical cancer; Metastasis

Indexed keywords

HERMES ANTIGEN; OLIGONUCLEOTIDE;

ADULT; ARTICLE; CANCER GRADING; CELL DIFFERENTIATION; CONTROLLED STUDY; EXON; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OLIGONUCLEOTIDE PROBE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADICAL HYSTERECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ANTIGENS, CD44; BLOTTING, SOUTHERN; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EXONS; FEMALE; HUMANS; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 0032401030     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00246-9     Document Type: Article

References (29)

1. 1. Wayner EA, Carter WG, Piotrowicz RS, Kunicki TJ. The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibits cell adhesion to fibronectin and reacts with platelet glycoproteins Ic-IIa. J Cell Biol 1988, 107, 1881-1891.
2. 2. Stamenkovic I, Aruffo A, Amiot M, Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991, 10, 343-348.
3. 3. Jalkanen S, Jalkanen M. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992, 116, 817-825.
4. 4. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996, 271, 509-512.
5. 5. Lesley J, Hyman R, Kincadr PW. CD44 and its interaction with extracellular matrix. Adv Immunol 1993, 54, 271-335.
6. 6. Screaton GR, Bell MV, Bell JI, Jackson DG. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 1993, 268, 12235-12238.
7. 7. Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991, 65, 13-24.
8. 8. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993, 177, 443-455.
9. 9. Mulder JWR, Kruyt PM, Sewnath M, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994, 344, 1470-1472.
10. 10. Kaufmann M, Heider KH, Sinn HP, Minckwitz G von, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995, 345, 615-619.
11. 11. Kainz C, Kohlberger P, Sliutz G, et al. Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol Oncol 1995, 57, 383-387.
12. 12. Kainz C, Kohlberger P, Tempfer C, et al. Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur J Cancer 1995, 31, 1706-1709.
13. 13. Biesold C, Køhler U, Horn LC, Bilek K, Kade R, Emmert C. CD44 exon v6 as a predictor of lymphatic metastases in cervical carcinoma - an immunocytochemical study of 94 cases. Arch Gynecol Obstet 1995, 256, 147-153.
14. 14. Speiser P, Wanner C, Tempfer C, et al. CD44 is an independent prognostic factor in early-stage cervical cancer. Int J Cancer 1997, 74, 185-188.
15. 15. Dall P, Heider KH, Hekele A, et al. Surface protein expression and messenger RNA-splicing analysis of CD 44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 1994, 54, 3337-3341.
16. 16. Shimabukuro K, Toyamo-Sorimachi N, Ozaki Y, et al. The expression patterns of standard and variant CD44 molecules in normal uterine cervix and cervical cancer. Gynecol Oncol 1997, 64, 26-34.
17. 17. Woerner SM, Givehchian M, Dürst M, et al. Expression of CD44 splice variants in normal, dysplastic, and neoplastic cervical epithelium. Clin Cancer Res 1995, 1, 1125-1132.
18. 18. Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992, 340, 1053-1058.
19. 19. Seki A, Kodama J, Miyagi Y, Kamimura S, Yoshinouchi M, Kudo T. Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int J Cancer 1997, 73, 33-37.
20. 20. Seki A, Nakamura K, Kodama J, et al. A close correlation between the c-erbB-2 gene amplification and local progression in endometrial adenocarcinoma. Eur J Gynecol Oncol 1998, 19, 90-92.
21. 21. Kan M, Aki M, Akiyama K, Naruo S, Kanayama H, Kagawa S. High-level expression of the CD44 variant sharing exon v10 in renal cancer. Jpn J Cancer Res 1995, 86, 847-853.
22. 22. Gunthert U, Stauder R, Mayer B, Terpe H, Finke L, Friedrichs K. Are CD44 variant isoforms involved in human tumor progression? Cancer Surv 1995, 24, 19-24.
23. 23. Herrlich P, Zoller M, Pals ST, Ponta H. CD44 splice variants: metastases meet lymphocytes. Immunol Today 1993, 14, 395-399.
24. 24. Rudy W, Hofmann M, Schwartz AR, et al. The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 1993, 53, 1262-1268.
25. 25. Stauder R, Eistere W, Thaler J, Gunthert U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood 1995, 8, 2885-2899.
26. 26. Friedrichs K, Franke F, Lisboa BW, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995, 55, 5424-5433.
27. 27. Higashikawa K, Yokozaki H, Ue T, et al. Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer 1996, 66, 11-17.
28. 28. Salmi M, Gron-Vita K, Sointu P, Grenman R, Kalimo H, Jalkanen S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993, 122, 431-442.
29. 29. Soukka T, Salmi M, Joensuu H, et al. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res 1997, 57, 2281-2189.